RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
Public ClinicalTrials.gov record NCT02128113. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study assesses the efficacy and safety of two concentrations of omaveloxolone (RTA 408) ophthalmic suspension for the prevention of corneal endothelial cell loss following cataract surgery.
Study identification
- NCT ID
- NCT02128113
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 307 participants
Conditions and interventions
Interventions
- Vehicle Ophthalmic Solution Drug
- Omaveloxolone Ophthalmic Suspension 0.5% Drug
- Omaveloxolone Ophthalmic Suspension 1% Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2014 (Actual)
- Primary completion
- Feb 28, 2015 (Actual)
- Completion
- Apr 30, 2015 (Actual)
- Last update posted
- Jun 3, 2025
2014 – 2015
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Harvard Eye Associates | Laguna Hills | California | 92653 | — |
| Hull Eye Center | Lancaster | California | 93534 | — |
| Argus Research | Cape Coral | Florida | 33904 | — |
| Levenson Eye Associates | Jacksonville | Florida | 32204 | — |
| Chicago Cornea Consultants | Hoffman Estates | Illinois | 60169 | — |
| JacksonEye | Lake Villa | Illinois | 60046 | — |
| Discover Vision Centers | Leawood | Kansas | 66211 | — |
| Opthalmic Consultants of Boston | Waltham | Massachusetts | 02451 | — |
| Talamo Hatch Laser Eye Consultants | Waltham | Massachusetts | 02451 | — |
| Associated Eye Care | Stillwater | Minnesota | 55082 | — |
| Comprehensive Eye Care | Washington | Missouri | 63090 | — |
| Alterman, Modi and Wolter | Poughkeepsie | New York | 12603 | — |
| Cincinnati Eye Institute | Cincinnati | Ohio | 45242 | — |
| R & R Eye Research | San Antonio | Texas | 78229 | — |
| See Clearly Vision Group | McLean | Virginia | 22102 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02128113, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 3, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02128113 live on ClinicalTrials.gov.